Is Merck Stock a Buy?
It's been a rough start to 2025 for (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with 7% revenue growth and earnings per share (EPS) of $1.72 for the quarter ended Dec. 31, weak sales in China and soft forward guidance were seen as a disappointment.
As of this writing, Merck's stock is down 16% year to date, hovering near its lowest point since 2022. Despite the recent setback, there are ample reasons for investors to maintain optimism. Below, I'll discuss whether now is a good time to buy Merck stock.
Merck is recognized for its extensive product portfolio covering treatments in areas like oncology, diabetes, cardiovascular diseases, vaccines, and infectious diseases. The company also operates a major animal-health segment, while engaging in biotechnology development beyond traditional pharmaceuticals. This diversified profile, with a long history of innovation, is a big part of the attraction of Merck stock as a possible investment.
Source Fool.com
Merck KGaA Stock
Our community is currently high on Merck KGaA with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 142 € shows a positive potential of 20.19% compared to the current price of 118.15 € for Merck KGaA.
